Kornimate/medical-research-clean huggingface dataset:
weight gain in extremely premature infant with targeted versus adjusted fortification

Conditions: Preterm; Very Low Birth Weight Infant; Feeding, Breast; Food, Fortified

Summary: investigation about the effect on weight gain in extremely low birth weight preterm with individualized fortification, according to human milk analysis versus fortification adjusted according to urea serum concentration.

1. study design this is an interventional, randomized, controlled study. 2. description of the study the very premature newborn will be identified by daily evaluation of the infants admitted for consultation in the income book. informed consent will be requested from the infant´s father, mother or legal guardian between the fifth and tenth day of life. fortification will be done according to the randomization group. 3. outline of the study design * excel calculation sheet of individualized supplementation according to the composition of breast milk in the target fortification group. methodology of analysis of breast milk in foss analyzer. * in the adjusted fortification group, urea concentration levels will be kept between 19-30 mg / dl * fenton curves or https://www.growthcalculator.org/ will be used for z-scores calculation. * growth speed calculation: weight gain: (1000x ln \[final weight / initial weight\]) / number of days. 4 duration of the study for each participant the duration of participation in the study and the fortification intervention period will be a maximum of 132 days.

Eligibility criteria:
inclusion criteria: 1. preterm infants born \<1000 g of birth weight that are fed with breast milk or donated milk. 2. written informed consent signed by the mother, father or legal guardian. 3. to tolerate enteral feeding, at least 100ml / kg / day. exclusion criteria: 1. non-premature or premature patients weighing ≥ 1000 gr. 2. patients with major malformations. 3. patients with diagnosed chromosomal diseases or of high diagnostic suspicion. 4. patients with short bowel syndrome or any surgery on the gastrointestinal tract.

Keywords: preterm nutrition human milk fortified
nd:yag laser and radiofrequency in treatment of fingernail psoriasis

Conditions: Nail Psoriasis

Summary: compare the effect of radiofrequency to long pulsed nd:yag 1064 nm laser in treatment of fingernail psoriasis.


Eligibility criteria:
inclusion criteria: * nail psoriasis exclusion criteria: * manual workers
valve hemodynamic optimization based on doppler-echocardiography vs catheterization measurements following viv tavr

Conditions: Aortic Valve Stenosis; Aortic Valve Regurgitation; Prosthesis Failure

Summary: data on valve performance following viv-tavr has usually been obtained with the use of doppler-echocardiography. however, some reports have shown significant discordances in the evaluation of mean transvalvular gradient between echocardiography and catheterization, with an overestimation of the real gradient with echo (vs. cath) in most cases. thus, the incidence of procedural-device failure may be lower than that reported in the viv-tavr literature,

this is a prospective, multicenter, randomized, single-blinded design trial including patients with surgical aortic bioprosthetic dysfunction in the presence of a stented surgical bioprosthesis with a labeled size ≤25 mm. following the heart team's decision to proceed with a viv-tavr procedure with the sapien 3 ultra valve (or its subsequent iterations), patients will be randomized to valve hemodynamic optimization according to doppler-echocardiography versus cardiac catheterization parameters.

Eligibility criteria:
inclusion criteria: * patients with surgical aortic bioprosthetic valve failure defined as severe aortic stenosis and/or regurgitation approved for a valve-in-valve procedure by the heart team * surgical stented bioprosthetic valve (label size ≤25 mm) * tavr with the sapien 3 ultra valve exclusion criteria: * stentless or sutureless surgical valves * trifecta bioprosthesis * hancock ii bioprosthesis * high-risk of coronary obstruction (defined either as a virtual transcatheter valve - coronary distance as evaluated by ct \<4 mm or based on the criterion of the heart team responsible for the procedure). * impossibility to obtain written informed consent
non-interventional, postmarketing surveillance study of nusinersen sodium injection

Conditions: Muscular Atrophy, Spinal

Summary: the primary objective of this study is to evaluate the safety of nusinersen sodium injection in the postmarketing setting in china.the secondary objectives are to collect data on the efficacy and the pharmacokinetics of nusinersen sodium injection in the post-marketing setting in china.


Eligibility criteria:
key inclusion criteria: * ability of the participant or his/her legally authorized representative (e.g., parent or legal guardian), as appropriate and applicable, to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information in accordance with national and local subject privacy regulations. * the decision to newly prescribe nusinersen sodium injection according to the local marketing authorization, including documentation of 5q sma diagnosis, has been made by the investigator and agreed to by the participant (or legally authorized representative) key exclusion criteria: * hypersensitivity to the active substance or any of the excipients of nusinersen sodium injection. * current or past administration of nusinersen sodium injection, in either a commercial or a clinical study setting. * other unspecified reasons that, in the opinion of the investigator or the sponsor, make the participant unsuitable for enrollment. note: other protocol defined inclusion/exclusion criteria may apply.
major bleeding risk associated with antithrombotics

Conditions: Major Haemorrhage

Summary: prospective, multicenter, observational study with a three-year inclusion period (from january 1, 2012 to december 31, 2015) and a 6-month follow-up

all adults subjects living in the five well-defined areas affiliated to the french national health insurance system and having had at least one reimbursement of any antithrombotic in the 3-year study period are identified by using data from the national health reimbursement database (système national d'information inter-régimes de l'assurance maladie, sniir-am). sniir-am contains individualized, anonymous and comprehensive data for all health spending reimbursements of affiliated subjects, including basic patient demographic data, medical drugs as well as outpatient medical care, prescribed or performed by health-care professionals from both public and private practices. this allows to calculate a denominator (number of person-years of anti-thrombotic drug exposure). crude incidence rates of major bleeding per 100 person-months are calculated in antithrombotic users, anticoagulants and others; stratification on a modified has-bled score allows fair comparison between anti-thrombotic drug classes.

Eligibility criteria:
inclusion criteria: * patient with major bleeding event associated with antithrombotic drug * patient older than 18 years old * information on 1 and 6-month follow-up is given pending non-opposition letter exclusion criteria: * patients with major bleeding events associated with antithrombotic during hospitalization * patients with intentional overdose with antithrombotic drugs * patients with multi-trauma * patients living outside the defined influence areas of the five participating cities

Keywords: major haemorrhage oral anticoagulation antiplatelet drugs gastrointestinal bleeding intracranial haemorrhage
apatinib mesylate combined with pemetrexed in the treatment of pretreated advanced non-squamous non-small cell lung cancer

Conditions: Nonsmall Cell Lung Cancer

Summary: the purpose of this study is to evaluate the efficacy of apatinib mesylate combined with pemetrexed alone in advanced non-small cell lung cancer patients in the second or second line of treatment of progression-free survival

it is a one-arm study. the progression-free survival will be evaluated.

Eligibility criteria:
inclusion criteria: 1. aged from 18 years to 70years. 2. histologically or cytologically confirmed non-squamous non-small cell lung cancer(stage iiib/iv). 3. measurable lesions as defined by recist criteria. 4. locally advanced lung cancer cannot treat with surgery, recurrent or metastatic lung cancer 5. ecog performance status (ps) of 0 to 1. 6. life expectancy ≥3 months. 7. informed consent. exclusion criteria: 1. squamous carcinoma (including adeno-squamous carcinoma), small cell lung cancer. 2. newly diagnosed central nervous system (cns) metastases that have not yet been definitively treated with surgery and/or radiation. 3. tumor invade big vessels or close to big vessels (less than 5mm) 4. obvious cavity or necrosis formed in the tumor 5. uncontrolled hypertension 6. myocardial ischemia or infarction more than stage ii, cardiac insufficiency. 7. abnormal coagulation (inr\>1.5 or pt\>uln+4, or aptt\>1.5 uln), bleeding tendency or receiving coagulation therapy 8. the active hbv or hcv infection 9. history of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix. 10. hemoptysis, more than 2.5ml daily 11. thrombosis in 12 months, including pulmonary thrombosis, stoke, or deep venous thrombosis. 12. unhealed bone fracture or wound for long time 13. received big surgery, had bone fracture or ulcer in 4 weeks. 14. urine protein≥++, or urine protein in 24 hours≥1.0g 15. use of cyp3a4 inhibitor within 7 days or cyp3a4 inducer within 12 days prior to enrollment 16. have received prior treatment with vegfr tki (bevacizumab is permitted). 17. pregnant or lactating woman, or woman unwilling to practice contraception during the study.

Keywords: apatinib pemetrexed nsclc
predictive value of vasodilator challenge for right heart failure after lvad implantation

Conditions: Right Heart Failure

Summary: prospective evaluation of the predictive value for post-lvad right ventricular failure (rhf) of pulmonary vasodilator challenge, in addition to current laboratory, echocardiographic and haemodynamic parameters. lvad candidates satisfying the inclusion criteria will undergo vasodilator challenge with sodium nitroprusside (ntp) infusion following the study protocol. thereafter, we will evaluate all data in order to determine which variables significantly correlate with rhf onset after lvad implantation.

inclusion criteria * age over 18 years old. * diagnosis of advanced heart failure with an indication for lvad implantation. * mean arterial pressure (map) \> 60 mmhg; mean pulmonary arterial pressure (mpap) \> 20 mmhg; pulmonary artery wedge pressure \>15 mmhg. * vasodilator challenge performed through ntp infusion. exclusion criteria * state of pregnancy. * inability to perform vasodilator challenge * need for extracorporeal membrane oxygenator or short-term right ventricular assist devices. * planned right ventricular assist device implantation in the peri-procedural setting. right heart catheterization (rhc) rhc will be performed under optimal medical therapy within 90 days before lvad implantation. vasodilator challenge will be performed through intravenous nitroprusside administration and titration (by 5 minutes intervals) until symptoms (flushing or hypotension) onset or systolic systemic pressure drops below 85 mmhg. dobutamine or phosphodiesterase inhibitors infusion could be performed at clinician's discretion. all haemodynamic measurements will be repeated after nitroprusside infusion and titration. right heart failure (rhf) post-operative rhf will be evaluated according to the definition proposed by the 2020 consensus statement of the mechanical circulatory support academic research consortium (1).

Eligibility criteria:
inclusion criteria * age over 18 years old. * diagnosis of advanced heart failure with an indication for lvad implantation. * mean arterial pressure (map) \> 60 mmhg; mean pulmonary arterial pressure (mpap) \> 20 mmhg; pulmonary artery wedge pressure \>15 mmhg. * vasodilator challenge performed through ntp infusion. exclusion criteria * state of pregnancy. * inability to perform vasodilator challenge * need for extracorporeal membrane oxygenator or short-term right ventricular assist devices. * planned right ventricular assist device implantation in the peri-procedural setting.

Keywords: lvad right heart failure advanced heart failure nitroprusside right heart catheterization
effect of the innovated seifi's functional appliance on skeletal and dentoalveolar changes of class ii/ 1, deep bite

Conditions: Orthodontic Appliance Design; Retrognathism; Malocclusion, Angle Class II; Deepbite

Summary: for improving the appearance of protruded upper front teeth when lower front teeth may touch palatal mucosa or have proximity to that; the innovated seifi's functional appliance may be used.

records will be obtained for each patient by the same operator before treatment and at the end of treatment. the appliance in this study is designed by prof. seifi and will be constructed by a well trained technician in the orthodontic laboratory of shahid beheshti school of dentistry under the supervision of the operator. the appliance consists of a jack screw in the midpalatal region plus two adams' clasps on the upper 1st molars and four kimia clasps on the buccal embrasure of the upper deciduous molars or premolars. for the mandibular portion there is an incisal clasp and incisors are capped by acrylic. the participants will be advised to use the appliance 24 hours per day except for meal times and when brushing the teeth or reading farsi or english in class room. each patient will pay his/her first recall visit to the orthodontic department one week after the appliance delivery and will be instructed to turn the maxillary expansion jack screw 1:4 turn twice a week to achieve coordination of the upper and lower arches in the transverse dimension. the patients will be evaluated over one month intervals and necessary adjustments were made. all cephalometric records, before and after treatment, will be coded and analyzed by a second party and the ultimate results and evaluations will be made.

Eligibility criteria:
inclusion criteria: * age between 8 - 12 years old * class π division 1 malocclusion (anb\>4) * increased over jet (\>4mm) * increased overbite (\>4mm) exclusion criteria: * history of previous orthodontic treatment * evidence of craniofacial syndromes

Keywords: seifi's functional, class ii/1, mandibular retrognathism
prevalence of cardiovascular disorders in patients aged 40 and more with schizophrenia

Conditions: Schizophrenia

Summary: schizophrenia is a psychiatric disorder, affecting 600,000 patients in france. patients with schizophrenia have life expectancy decrease from 10 to 20 years because of cardiovascular death. cardiovascular risk factors are numerous: inadequate diet, smoking, alcohol consumption, diabetes, obesity. primary prevention of cardiovascular risk in patients suffering from schizophrenia is difficult because of understaff in general practitioners and psychiatrists.

the aim of the study is to describe prevalence of cardiovascular disorders in patients aged 40 and more with schizophrenia.

Eligibility criteria:
inclusion criteria: * male or female * aged of 40 and more * with schizophrenia * agreeing to participate in the study

Keywords: schizophrenia cardiovascular disorders prevalence
trial of cyclosporine in the acute phase of leber hereditary optic neuropathy

Conditions: Leber Hereditary Optic Neuropathy

Summary: the leber hereditary optic neuropathy is a genetic disorder caused by maternal transmission of mitochondrial desoxirobonucleid acid mutations. it is manifested by a rapidly progressive blindness, profound, due to atrophic optic nerve. the visual loss is primarily unilateral bilateralisation taking place in the vast majority of cases in weeks or months. the neuro-cardio-protective properties of cyclosporine (and its analogs specifically targeting the anti-apoptotic mechanisms) are particularly promising. the investigators hypothesis is that cyclosporine may limit apoptosis during the acute phase of the disease process and would limit the loss of visual acuity and improve the visual prognosis of these patients.


Eligibility criteria:
inclusion criteria: * patient with the mutation confirmed by molecular analysis * patient with a recent loss of monocular vision (≤ 6 months) * voluntarily patient consent exclusion criteria: * patient who have not given their written and informed consent signed * against indication of cyclosporine * no drug compliance to previous inclusion * no national health insurance affiliation * pregnant women or lactating * women who could become pregnant during the study period and with no contraception * private patients of their liberty by judicial or administrative decision, or patients under supervision
adjuvant oophorectomy and tamoxifen in premenopausal women with hormone receptor-positive breast cancer

Conditions: Breast Cancer

Summary: this trial tests surgical oophorectomy (removal of ovaries) plus tamoxifen, done at different times in the menstrual cycle, as adjuvant therapy for invasive breast cancer in 510 premenopausal women with hormone receptor-positive breast cancer. this study is recruiting at hospitals in philippines, vietnam, and morocco.


Eligibility criteria:
inclusion criteria: * open for accrual in asia only * female age 18-50, * premenopausal with regular cycles (\>25-35 in length) * fine-needle aspiration diagnosis * stage ii-iiia hormone receptor positive invasive breast cancer * no prior radiation or chemotherapy * must be surgical candidate for bilateral oophorectomy

Keywords: asian premenopausal women oophorectomy
knowledge, attitude and practice among undergraduate dental students, cairo university towards ergonomics

Conditions: Knowledge, Attitudes, Practice

Summary: this study will evaluate knowledge, attitude, and practice of fifth-year dental students cairo university toward ergonomics

ergonomic is the study of people and their working environment. ergonomic consequently is the science concerned with designing products and procedures to maximize efficiency and safety. the world health organization defines musculoskeletal disorder (msd) as "a disorder of the muscles tendons, joints, intervertebral discs, peripheral nerves, and vascular system''. the musculoskeletal disorders are common among medical professionals, and especially dentists and dental hygienists, because of the prevalence of different postures in dental procedures, prolonged stature, unsupported sitting, griping smaller and thin instruments for a longer time and limited access during dental procedures. musculoskeletal disorder (msd) affect muscle, joints, tendons, ligaments, and nerves and caused by work itself or by working environment. it has been reported that back pain is the most common followed by neck pain and shoulder pain. if early signs and symptoms are noted, with the understanding of mechanisms of progression of the disease, msds can be prevented at earlier stage. (gupta et al., 2014), state some signs and symptoms of msd on dentists: signs of msds: * decreased range of motion. * loss of normal sensation. * decreased grip strength. * loss of normal movement. * loss of coordination. symptoms of msds: * excessive fatigue in the shoulders and neck. * tingling, burning or other pain in arms. * weak grip, cramping of hands. * numbness in fingers and hands. * clumsiness and dropping of objects. * hypersensitivity in hands and fingers. goals of ergonomics according to (pendyala and karunakar, 2014) : * prevention of work-related musculoskeletal disorders and conditions which might lead to it. * increasing safety and productivity. * enhanced performance by eliminating unnecessary effort. * improving the standard of care to the patient. so this study is conducted to assess the knowledge, attitude, and practice (kap) among fifth-year undergraduate dental students, cairo university towards ergonomics

Eligibility criteria:
inclusion criteria: * fifth-year undergraduate dental students, cairo university at the time of the study exclusion criteria: * refusal to participate

Keywords: knowledge attitude practice kap ergonomics dental ergonomics
concurrent radiotherapy with weekly topotecan for primary treatment of inoperable localized non-small cell lung cancer

Conditions: Lung Cancer

Summary: given the activity of single-agent topotecan in nsclc, there is both scientific rationale and a medical interest in studying this agent in combination with radiation. in addition, topotecan administered on a weekly basis offers advantages over the daily x 5 regimen, i.e., the convenience of administration and fewer visits to the clinic.

this is a study of chemoradiation for patient with inoperable non small cell lung cancer with poor pulmonary function. these patients have usually very limited treatment options because of the compromised lung function. chemoradiation is usually superior to radiation alone, but has not been extensively tested in this patient population. topotecan is a drug approved for lung cancer that has synergistic activity with radiation. the study will determine what is the safest dose of topotecan to use with radiation in this patient population

Eligibility criteria:
inclusion criteria: * patients with histologically proven non-small cell lung cancer stage i to iiia. * inoperable lung cancer because of poor respiratory lung function, or other medical reasons, as determined by the thoracic surgeon. * ps \< 2 * age \> 18 years * life expectancy of \> 12 weeks * normal hematologic, liver, and renal function * no metastatic disease as determined by ct-pet scanning and bone scan. * no brain metastasis by mri * no contraindication to radiotherapy exclusion criteria: * patients with uncontrolled cns metastases. * active systemic infection. * serious, uncontrolled intercurrent medical or psychiatric illness. * secondary active primary malignancy. * inability to comply with requirements of the study. * any metastases outside of the mediastinum * histologically positive pleural or pericardial effusion * any chemotherapy within five years prior to enrollment on this protocol * prior radiotherapy administered to the chest * women who are pregnant or lactating * fev1 \< 1 liter/minute